340
Views
3
CrossRef citations to date
0
Altmetric
Research Articles

Inhibition of the predicted allosteric site of the SARS-CoV-2 main protease through flavonoids

, , , , , & ORCID Icon show all
Pages 9103-9120 | Received 23 May 2022, Accepted 19 Oct 2022, Published online: 20 Nov 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Florbela Pereira, Loay Bedda, Mohamed A. Tammam, Abdul Kader Alabdullah, Reem Arafa & Amr El-Demerdash. (2023) Investigating the antiviral therapeutic potentialities of marine polycyclic lamellarin pyrrole alkaloids as promising inhibitors for SARS-CoV-2 and Zika main proteases (Mpro). Journal of Biomolecular Structure and Dynamics 0:0, pages 1-19.
Read now
Urvashee Gogoi, Neelutpal Gogoi, Sanchaita Rajkhowa, Shah Alam Khan, Nisreen Daffa Alla Omer Hajedris, Nawal Al-Hoshani, Samia T. Al-Shouli & Aparoop Das. Expanding the therapeutic arsenal against cancer: a computational investigation of hybrid xanthone derivatives as selective Topoisomerase 2α ATPase inhibitors. Journal of Biomolecular Structure and Dynamics 0:0, pages 1-30.
Read now

Articles from other publishers (1)

Shah Faisal, Syed Lal Badshah, Bibi Kubra, Abdul-Hamid Emwas & Mariusz Jaremko. (2023) Alkaloids as potential antivirals. A comprehensive review. Natural Products and Bioprospecting 13:1.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.